News articles about Tetraphase Pharmaceuticals (NASDAQ:TTPH) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Tetraphase Pharmaceuticals earned a news impact score of 0.20 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 45.5809800090973 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the news headlines that may have impacted Accern Sentiment’s scoring:
- Tetraphase Pharmaceuticals, Inc (NASDAQ:TTPH) Trading Volume Significantly Higher - Modern Readers (modernreaders.com)
- Fmr LLC Has $12.66 Million Position in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) (elcumanes.com)
- Tetraphase Pharmaceuticals, Inc. (TTPH) Expected to Announce Earnings of -$0.65 Per Share (americanbankingnews.com)
- What The Sell-Side Thinks Of DDR Corp. (DDR), Tetraphase Pharmaceuticals, Inc. (TTPH) - StockNewsMagazine (stocknewsmagazine.com)
- Tetraphase Pharmaceuticals, Inc. – Value Analysis (NASDAQ:TTPH) : August 4, 2017 (finance.yahoo.com)
Several analysts recently weighed in on the company. Needham & Company LLC restated a “hold” rating on shares of Tetraphase Pharmaceuticals in a research note on Thursday, July 27th. BMO Capital Markets restated an “outperform” rating and set a $13.00 target price (up previously from $12.00) on shares of Tetraphase Pharmaceuticals in a research note on Wednesday, July 26th. Stifel Nicolaus upgraded Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and increased their target price for the company from $8.00 to $15.00 in a research note on Wednesday, July 26th. Zacks Investment Research downgraded Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, May 10th. Finally, HC Wainwright assumed coverage on Tetraphase Pharmaceuticals in a research note on Tuesday, July 11th. They set a “buy” rating and a $15.00 target price for the company. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $10.25.
Shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) traded down 0.963% during mid-day trading on Friday, reaching $5.655. The company had a trading volume of 2,193,915 shares. The firm’s 50-day moving average is $7.40 and its 200 day moving average is $6.92. The company’s market capitalization is $288.70 million. Tetraphase Pharmaceuticals has a 12 month low of $3.11 and a 12 month high of $9.93.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by $0.07. Tetraphase Pharmaceuticals had a negative return on equity of 79.79% and a negative net margin of 2,092.20%. The business had revenue of $1.59 million for the quarter, compared to the consensus estimate of $1.54 million. During the same quarter in the previous year, the business posted ($0.47) EPS. The company’s revenue for the quarter was up 28.2% on a year-over-year basis. On average, equities research analysts predict that Tetraphase Pharmaceuticals will post ($2.65) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://stocknewstimes.com/2017/08/06/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-tetraphase-pharmaceuticals-ttph-share-price-updated-updated.html.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
